■髋关节骨性关节炎(OA)是导致全球残疾和发病的主要原因之一。据估计,全球有9.2%的人年龄在45岁以上。常规治疗方式具有局限性和副作用。为了克服这些限制,在过去的十年里,人们对使用自体来源的直系生物制剂(包括富血小板血浆(PRP))越来越感兴趣,骨髓抽吸物浓缩物(BMAC)和脂肪组织来源的制剂。这篇综述定性地介绍了体外,临床前,临床和正在进行的临床研究探索BMAC治疗髋部OA的安全性和有效性。
■电子数据库搜索是通过PubMed完成的,Embase,WebofScience,Scopus,ProQuest和GoogleScholar至2024年2月。使用的搜索词为\"骨关节炎\"或\"髋骨关节炎\"或\"正畸学\"或\"正畸学治疗的疗效或使用\"或\"骨髓浓缩物\"或\"骨髓抽吸物浓缩物\",和“BMAC”。纳入标准是以英语撰写的任何水平证据的临床研究,发表至2024年2月,评估关节内给药BMAC治疗髋关节OA的安全性和有效性。
■本综述共纳入5项研究,以进行定性数据综合。参与该研究的患者总数为182,在一项研究中从4到112不等。在整个研究期间没有报告不良事件。此外,关节内给予BMAC导致疼痛减轻,改善功能和整体生活质量(QoL)。
■本综述的结果表明,BMAC的给药在减轻疼痛方面是安全和潜在有效的,根据纳入的研究,在短期和中期平均随访中改善髋关节OA患者的功能和总体QoL。尽管如此,动力更充足,多中心,prospective,双盲,有必要进行长期随访的非随机和随机对照试验,以确定BMAC用于治疗髋部OA的长期安全性和有效性,并证明其常规临床应用的合理性.
UNASSIGNED: Hip osteoarthritis (OA) is one of the leading causes of disability and morbidity worldwide. It is estimated to affect 9.2% individuals globally with age over 45 years. Conventional treatment modalities have limitations and side-effects. To overcome these limitations, over the last decade, there has been an increased interest in the use of
orthobiologics derived from autologous sources including platelet-rich plasma (PRP), bone-marrow aspirate concentrate (BMAC) and adipose tissue derived formulations. This review qualitatively presents the in-vitro, pre-clinical, clinical and on-going clinical studies exploring the safety and efficacy of BMAC for management of hip OA.
UNASSIGNED: The electronic database search was done through PubMed, Embase, Web of Science, Scopus, ProQuest and Google Scholar till February 2024. The search terms used were \"osteoarthritis\" OR \"hip osteoarthritis\" OR \"
orthobiologics\" OR \"efficacy or use of orthobiologic treatment\" OR \"bone-marrow concentrate\" OR \"bone-marrow aspirate concentrate\", AND \"BMAC\". The inclusion criteria were clinical studies of any level of evidence written in the English language, published till February 2024, evaluating the safety and efficacy of intra-articular administration of BMAC for the management of hip OA.
UNASSIGNED: A total of 5 studies were included in this review for qualitative data synthesis. The total number of patients who participated in the study was 182, ranging from 4 to 112 in a single study. No adverse events were reported throughout the duration of the study. In addition, intra-articular administration of BMAC led to reduced pain, and improved function and overall quality of life (QoL).
UNASSIGNED: The results from this review demonstrated that administration of BMAC is safe and potentially efficacious in terms of reducing pain, improving function and overall QoL of patients with hip OA in short- and mid-term average follow-up based on the included studies. Nonetheless, more adequately powered, multi-center, prospective, double-blind, non-randomized and randomized controlled trials with long-term follow-up are warranted to establish long-term safety and efficacy of BMAC for management of hip OA and justify its routine clinical use.